NCT05634694

Study on Consistency Evaluation for Drug Sensitivity of Patient-Derived Organoid Model From Cholangiocarcinoma Patients

Status unknown Last updated 2 December 2022

What this trial tests

trial testing No interventions. in Cholangiocarcinoma in 40 participants. Status unknown.

Timeline

30 November 2022

Primary endpoint
1 December 2023

1 December 2024

Quick facts

Lead sponsor	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	40
Start date	30 November 2022
Primary completion	1 December 2023
Estimated completion	1 December 2024
Sites	1 location across China

Drugs / interventions tested

• No interventions.

Conditions studied

• Cholangiocarcinoma — all drugs for Cholangiocarcinoma →

Sponsor

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Who can join

Adults 18 to 75, any sex, with Cholangiocarcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a single-center, prospective, observational and exploratory clinical study. The object of this study is to evaluate the consistency and accuracy of patient-derived organoid model of cholangiocarcinoma to predict the clinical chemotherapeutic efficacy, as well as the possibility of guiding the adjuvant chemotherapy.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Organoids: The current status and biomedical applications.
   Yang S, Hu H, Kung H, Zou R, et al · · 2023 · cited 162× · PMID 37215622 · DOI 10.1002/mco2.274
2. Patient-derived tumor organoids: a new avenue for preclinical research and precision medicine in oncology.
   Thorel L, Perréard M, Florent R, Divoux J, et al · · 2024 · cited 90× · PMID 38945959 · DOI 10.1038/s12276-024-01272-5
3. Organoids: development and applications in disease models, drug discovery, precision medicine, and regenerative medicine.
   Yao Q, Cheng S, Pan Q, Yu J, et al · · 2024 · cited 40× · PMID 39309690 · DOI 10.1002/mco2.735
4. Tumour organoids and assembloids: Patient-derived cancer avatars for immunotherapy.
   Mei J, Liu X, Tian HX, Chen Y, et al · · 2024 · cited 25× · PMID 38664597 · DOI 10.1002/ctm2.1656
5. Liver organoids: Current advances and future applications for hepatology.
   Kim Y, Kang M, Mamo MG, Adisasmita M, et al · · 2025 · cited 7× · PMID 39722609 · DOI 10.3350/cmh.2024.1040
6. The application of organoids in treatment decision-making for digestive system cancers: progress and challenges.
   Wang Y, Zhang L, Wang LZ, Cao Y, et al · · 2025 · cited 4× · PMID 40855314 · DOI 10.1186/s12943-025-02429-0
7. Human patient derived organoids: an emerging precision medicine model for gastrointestinal cancer research.
   Yan S, He Y, Zhu Y, Ye W, et al · · 2024 · cited 4× · PMID 38638528 · DOI 10.3389/fcell.2024.1384450
8. Advances in precision oncology using patient-derived organoids and functional biomaterials.
   Singh H, Mijakovic I, Singh P. · · 2025 · PMID 41098309 · DOI 10.3389/fcell.2025.1670328